Core Viewpoint - Company has received approval from the National Medical Products Administration for clinical trials of Relugolix tablets, aimed at treating prostate cancer [1] Group 1: Company Developments - Company announced the approval of clinical trials for Relugolix tablets, a GnRH receptor antagonist, primarily used for prostate cancer and endometriosis treatment [1] - Current prostate treatment portfolio includes the marketed drug Apalutamide tablets and the clinical trial stage LH-2103 capsules [1] - Approval for clinical trials does not immediately impact the company's revenue or operational performance significantly [1] Group 2: Regulatory Aspects - The approval from the National Medical Products Administration allows the company to conduct clinical trials, which must be followed by further review and approval before the drug can be marketed [1]